Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Stoschitzky, K.
Polypill Strategy in Secondary Cardiovascular Prevention
NEW ENGL J MED. 2022; 387(23): 2196-2198. Doi: 10.1056/NEJMc2213446
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Stoschitzky Kurt
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: To the Editor: In their article on the Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial, Castellano et al. (Sept. 15 issue)(1) report that treatment with a polypill containing aspirin, ramipril, and atorvastatin was associated with a significantly lower risk of cardiovascular events than usual care in older patients with recent myocardial infarction. However, this polypill did not contain a beta-blocker, although it is has been known for decades that these drugs are particularly effective after myocardial infarction(2,3) and their use is recommended in current guidelines.(4,5) Therefore, can the SECURE investigators report data to answer the question of . . .